

MOLECULAR CANCER THERAPEUTICS

TABLE OF CONTENTS

HIGHLIGHTS

323 Selected Articles from This Issue

SMALL MOLECULE THERAPEUTICS

325 ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine

A C Shripad V. Bhagwat, William T. McMillen, Shufen Cai, Baohui Zhao, Matthew Whitesell, Weihua Shen, Lisa Kindler, Robert S. Flack, Wenjuan Wu, Bryan Anderson, Yan Zhai, Xiu-Juan Yuan, Meghann Pogue, Robert D. Van Horn, Xi Rao, Denis McCann, Andrew J. Dropsey, Jason Manro, Jennie Walgren, Eunice Yuen, Michael J. Rodriguez, Gregory D. Plowman, Ramon V. Tiu, Sajan Joseph, and Sheng-Bin Peng

337 Targeting of β -Catenin Reverses Radioresistance of Cervical Cancer with the *PIK3CA*-E545K Mutation

A C Wei Jiang, Yutuan Wu, Tiancong He, Hanting Zhu, Guihao Ke, Libing Xiang, and Huijuan Yang

348 An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance

Shanshan Deng, Raisa I. Krutilina, Qinghui Wang, Zongtao Lin, Deanna N. Parke, Hilaire C. Playa, Hao Chen, Duane D. Miller, Tiffany N. Seagroves, and Wei Li

364 Therapeutic Targeting of MDR1 Expression by ROR γ Antagonists Resensitizes Cross-Resistant CRPC to Taxane via Coordinated Induction of Cell Death Programs

Yongqiang Wang, Zenghong Huang, Christopher Z. Chen, Chengfei Liu, Christopher P. Evans, Allen C. Gao, Fangjian Zhou, and Hong-Wu Chen

375 A Potent Blood-Brain Barrier-Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient-Derived Orthotopic Xenograft Model

Yukino Machida, Makoto Nakagawa, Hironori Matsunaga, Masayuki Yamaguchi, Yoko Ogawara, Yutaka Shima, Kazutsune Yamagata, Takuo Katsumoto, Ayuna Hattori, Masato Itoh, Takahiko Seki, Yumi Nishiya, Koichi Nakamura, Kanae Suzuki, Tomoki Imaoka, Daichi Baba, Makoto Suzuki, Oltea Sampetean, Hideyuki Saya, Koichi Ichimura, and Issay Kitabayashi

384 Ibrutinib Potentiates Antihepatocarcinogenic Efficacy of Sorafenib by Targeting EGFR in Tumor Cells and BTK in Immune Cells in the Stroma

Cho-Hao Lin, Khadija H. Elkholy, Nissar A. Wani, Ding Li, Peng Hu, Juan M. Barajas, Lianbo Yu, Xiaoli Zhang, Samson T. Jacob, Wasif N. Khan, Xue-Feng Bai, Anne M. Noonan, and Kalpana Ghoshal

397 The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor

Kathryn M. Lemberg, Liang Zhao, Ying Wu, Vijayabhaskar Veeravalli, Jesse Alt, Joanna Marie H. Aguilar, Ranjeet P. Dash, Jenny Lam, Lukáš Tenora, Chabely Rodriguez, Michael T. Nedelcovych, Cory Brayton, Pavel Majer, Jaishri O. Blakeley, Rana Rais, and Barbara S. Slusher

409 Selective PRMT5 Inhibitors Suppress Human CD8⁺ T Cells by Upregulation of p53 and Impairment of the AKT Pathway Similar to the Tumor Metabolite MTA

Carolin Dorothea Strobl, Stefanie Schaffer, Tabea Haug, Simon Völkl, Katrin Peter, Katrin Singer, Martin Böttcher, Dimitrios Mougiakakos, Andreas Mackensen, and Michael Aigner

420 A Novel Sulforaphane-Regulated Gene Network in Suppression of Breast Cancer-Induced Osteolytic Bone Resorption

Subrata K. Pore, Eun-Ryeong Hahm, Su-Hyeong Kim, Krishna B. Singh, Lea Nyiranshuti, Joseph D. Latoche, Carolyn J. Anderson, Juraj Adamik, Deborah L. Galson, Kurt R. Weiss, Rebecca J. Watters, Boeun Lee, Prashant N. Kumta, and Shivendra V. Singh

TABLE OF CONTENTS

- 432** **The Existence of MTH1-independent 8-oxodGTPase Activity in Cancer Cells as a Compensatory Mechanism against On-target Effects of MTH1 Inhibitors**
Govindi J. Samaranayake, Clara I. Troccoli, Ling Zhang, Mai Huynh, Christina J. Jayaraj, Debin Ji, Lisa McPherson, Yoshiyuki Onishi, Dao M. Nguyen, David J. Robbins, Mahsa Karbaschi, Marcus S. Cooke, Antonio Barrientos, Eric T. Kool, and Priyamvada Rai
- 447** **Development of a Novel Multi-Isoform ALDH Inhibitor Effective as an Antimelanoma Agent**
Saketh S. Dinavahi, Raghavendra Gowda, Krishne Gowda, Christopher G. Bazewicz, Venkat R. Chirasani, Madhu Babu Battu, Arthur Berg, Nikolay V. Dokholyan, Shantu Amin, and Gavin P. Robertson
- 460** **A Phase I Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer**
Ryan J. Sullivan, Antoine Hollebecque, Keith T. Flaherty, Geoffrey I. Shapiro, Jordi Rodon Ahnert, Michael J. Millward, Wei Zhang, Ling Gao, Amanda Sykes, Melinda D. Willard, Danni Yu, Andrew E. Schade, KrisAnne Crowe, Daniel L. Flynn, Michael D. Kaufman, James R. Henry, Sheng-Bin Peng, Karim A. Benhadji, Ilaria Conti, Michael S. Gordon, Ramon V. Tiu, and David S. Hong
- 468** **On-Target Pharmacodynamic Activity of the PI3K Inhibitor Copanlisib in Paired Biopsies from Patients with Malignant Lymphoma and Advanced Solid Tumors**
A C Franck Morschhauser, Jean-Pascal Machiels, Gilles Salles, Sylvie Rottey, Simon A.J. Rule, David Cunningham, Frederic Peyrade, Christophe Fruchart, Hendrik-Tobias Arkenau, Isabelle Genvresse, Li Liu, Karl Köchert, Kui Shen, Christoph Kneip, Carol E. Peña, Joachim Grevel, Jun Zhang, Galia Cisternas, Susanne Reschke, Camille Granvil, and Ahmad Awada
- 479** **Inhibition of Y Box Binding Protein 1 Suppresses Cell Growth and Motility in Colorectal Cancer**
A C Areumnuri Kim, Sehwan Shim, Young-heon Kim, Min-Jung Kim, Sunhoo Park, and Jae Kyung Myung
- 502** **Anticancer Activity of ZnO Nanoparticles against Human Small-Cell Lung Cancer in an Orthotopic Mouse Model**
A C Ryosuke Tanino, Yoshihiro Amano, Xuexia Tong, Rong Sun, Yukari Tsubata, Mamoru Harada, Yasuhisa Fujita, and Takeshi Isobe
- 513** **Toxicology and Pharmacokinetic Studies in Mice and Nonhuman Primates of the Nontoxic, Efficient, Targeted Hexameric FasL: CTLA4-FasL**
Efi Makdasi, Shira Amsili, Alexandra Aronin, Tatyana B. Prigozhina, Kobi Tzdaka, Yosi Meir Gozlan, Liat Ben Gigi-Tamir, Jitka Yehudith Sagiv, Fanny Shkedy, Noam Shani, Mark L. Tykocinski, and Michal Dranitzki Elhalel
- CANCER BIOLOGY AND TRANSLATIONAL STUDIES**
- 525** **Dual-Mechanism ERK1/2 Inhibitors Exploit a Distinct Binding Mode to Block Phosphorylation and Nuclear Accumulation of ERK1/2**
A C Andrew M. Kidger, Joanne M. Munck, Harpreet K. Saini, Kathryn Balmanno, Emma Minihane, Aurelie Courtin, Brent Graham, Marc O'Reilly, Richard Odle, and Simon J. Cook
- 540** **Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF- κ B Pathway in Preclinical Models of Pediatric High-Grade Glioma**
John A. DeSisto, Patrick Flannery, Rakeb Lemma, Amrita Pathak, Shelby Mestnik, Natalie Philips, Natalie J. Bales, Trinayan Kashyap, Erin Moroze, Sujatha Venkataraman, Andrew L. Kung, Bruce D. Carter, Yosef Landesman, Rajeev Vibhakar, and Adam L. Green
- 552** **Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase Inhibition**
A C Agata Okonska, Saskja Bühler, Vasundhara Rao, Manuel Ronner, Maxime Blijlevens, Ida H. van der Meulen-Muileman, Renee X. de Menezes, Martin Wipplinger, Kathrin Oehl, Egbert F. Smit, Walter Weder, Rolf A. Stahel, Lorenza Penengo, Victor W. van Beusechem, and Emanuela Felley-Bosco
- 564** **Ceramide-Rubusoside Nanomicelles, a Potential Therapeutic Approach to Target Cancers Carrying p53 Missense Mutations**
Sachin K. Khiste, Zhijun Liu, Kartik R. Roy, Mohammad B. Uddin, Salman B. Hosain, Xin Gu, Sami Nazzal, Ronald A. Hill, and Yong-Yu Liu
- 575** **Radiation Responses of 2D and 3D Glioblastoma Cells: A Novel, 3D-specific Radioprotective Role of VEGF/ Akt Signaling through Functional Activation of NHEJ**
Natividad Gomez-Roman, Ming Y Chong, Sandeep K. Chahal, Seamus P. Caragher, Mark R. Jackson, Katrina H. Stevenson, Sidhartha A. Dongre, and Anthony J. Chalmers

LARGE MOLECULE THERAPEUTICS

- 490** **10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models**
Dipti Thakkar, Vicente Sancenon, Marvin M. Taguiani, Siyu Guan, Zhihao Wu, Eric Ng, Konrad H. Paszkiewicz, Piers J. Ingram, and Jerome D. Boyd-Kirkup

TABLE OF CONTENTS

590 Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment

Ximena Rosas-Plaza, Gerda de Vries, Gert Jan Meersma, Albert J.H. Suurmeijer, Jourik A. Gietema, Marcel A.T.M. van Vugt, and Steven de Jong

602 Amplification of the Mutation-Carrying BRCA2 Allele Promotes RAD51 Loading and PARP Inhibitor Resistance in the Absence of Reversion Mutations

Pyoung Hwa Park, Tomomi M. Yamamoto, Hua Li, Allen L. Alcivar, Bing Xia, Yifan Wang, Andrea J. Bernhardt, Kristen M. Turner, Andrew V. Kossenkov, Zachary L. Watson, Kian Behbakht, Silvia Casadei, Elizabeth M. Swisher, Paul S. Mischel, Neil Johnson, and Benjamin G. Bitler

614 Targeting the MET Receptor Tyrosine Kinase as a Strategy for Radiosensitization in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

Lluís Nisa, Paola Francica, Roland Giger, Matúš Medo, Olgun Elicin, Manja Friese-Hamim, Claudia Wilm, Christopher Stroh, Beat Bojaxhiu, Aurélie Quintin, Marco D. Caversaccio, Matthias S. Dettmer, Mélanie Buchwalder, Tess M. Brodie, Daniel M. Aebersold, Yitzhak Zimmer, Thomas E. Carey, and Michaela Medová

627 Rational Combination Therapy for Melanoma with Dinaciclib by Targeting BAK-Dependent Cell Death

Xiaoou Xu, Shizuka Eshima, Shinichiro Kato, David E. Fisher, Hiroaki Sakurai, Yoshihiro Hayakawa, and Satoru Yokoyama

637 A Synergistic Anticancer FAK and HDAC Inhibitor Combination Discovered by a Novel Chemical-Genetic High-Content Phenotypic Screen

John C. Dawson, Bryan Serrels, Adam Byron, Morwenna T. Muir, Ashraff Makda, Amaya García-Muñoz, Alex von Kriegsheim, Daniel Lietha, Neil O. Carragher, and Margaret C. Frame

650 Serum- and Glucocorticoid-inducible Kinase 1 is Essential for Osteoclastogenesis and Promotes Breast Cancer Bone Metastasis



Zheng Zhang, Qian Xu, Chao Song, Baoguo Mi, Honghua Zhang, Honglei Kang, Huiyong Liu, Yunlong Sun, Jia Wang, Zhuowei Lei, Hanfeng Guan, and Feng Li

661 CRISPR Screening Identifies WEE1 as a Combination Target for Standard Chemotherapy in Malignant Pleural Mesothelioma

Duo Xu, Shun-Qing Liang, Haitang Yang, Rémy Bruggmann, Sabina Berezowska, Zhang Yang, Thomas Michael Marti, Sean Ralph Robert Hall, Yanyun Gao, Gregor J. Kocher, Ralph A. Schmid, and Ren-Wang Peng

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

673 PET Imaging of the EPR Effect in Tumor Xenografts Using Small 15 nm Diameter Polyethylene Glycols Labeled with Zirconium-89

Denis R. Beckford Vera, Shaun D. Fontaine, Henry F. VanBrocklin, Brian R. Hearn, Ralph Reid, Gary W. Ashley, and Daniel V. Santi

680 Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer



Márcia A. Inda, Erik J. Blok, Peter J.K. Kuppen, Ayoub Charehbili, Eveline C. den Biezen-Timmermans, Anne van Brussel, Sevgi E. Fruytier, Elma Meershoek-Klein Kranenbarg, Susan Kloet, Bart van der Burg, John W.M. Martens, Andrew H. Sims, Arran K. Turnbull, J. Michael Dixon, Wim Verhaegh, Judith R. Kroep, Cornelis J.H. van de Velde, and Anja van de Stolpe

690 Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma

Amin H. Nassar, Lana Hamieh, Kathryn P. Gray, Aaron R. Thorner, Andre P. Fay, Kathryn D. Lasseter, Sarah Abou Alaiwi, Pier Vitale Nuzzo, Ronan Flippot, Katherine M. Krajewski, Sabina Signoretti, Toni K. Choueiri, and David J. Kwiatkowski

MODELS AND TECHNOLOGIES

697 Therapeutic Breast Reconstruction Using Gene Therapy-Delivered IFN γ Immunotherapy

Christopher R. Davis, Peter A. Than, Sacha M.L. Khong, Melanie Rodrigues, Michael W. Findlay, Daniel J. Navarrete, Shadi Ghali, Jayant S. Vaidya, and Geoffrey C. Gurtner

706 Hyaluronidase-Expressing *Salmonella* Effectively Targets Tumor-Associated Hyaluronic Acid in Pancreatic Ductal Adenocarcinoma

Nancy D. Ebel, Edith Zuniga, Kevin B. Passi, Lukas J. Sobocinski, and Edwin R. Manuel

717 The First Clinical Use of a Recombinant *Lactococcus lactis* Expressing Human Papillomavirus Type 16 E7 Oncogene Oral Vaccine: A Phase I Safety and Immunogenicity Trial in Healthy Women Volunteers

Amir Hossein Mohseni, Sedigheh Taghinezhad-S, and Hossein Keyvani


AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

TABLE OF CONTENTS

ABOUT THE COVER

Triple negative breast cancer (TNBC) is highly aggressive and is characterized by poor prognosis and increased risk of visceral metastases. On the cover, Deng and colleagues demonstrate the efficacy of a colchicine binding site inhibitor, VERU-111, on tubulin in TNBC cells. VERU-111 showed potent cytotoxicity against TNBC in vitro. In vivo, orally administered VERU-111 effectively inhibited the tumor growth in two aggressive TNBC xenograft models, including a taxane-resistant PDX model. VERU-111 significantly repressed visceral metastasis in both xenograft models and in an experimental metastasis model, suggesting VERU-111 is a promising drug candidate for the treatment of metastatic TNBC, potentially including patients who progress on taxanes. Read the article on page 348.



Molecular Cancer Therapeutics

19 (2)

Mol Cancer Ther 2020;19:323-727.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/19/2>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/19/2>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.